Samrat Pharmachem ‘s Q2 Update: Revenue Decreases by 12% Year-on-Year

The comprehensive analytics outlining the performance and outlook of Samrat Pharmachem Ltd.‘s stock. This analysis encompasses various metrics including stock performance, investor sentiment, market trends, future outlook, risk factors, investment opportunities, long-term strategy, dividend policy, analyst insights, and the overall risk-reward profile. These insights aim to provide investors with a holistic understanding of the company”s stock, enabling informed decision-making and strategic investment planning.

Today, we’re looking at Samrat Pharmachem Ltd.’s financial performance for the Q2(Sep 2024-25).Starting with the top line, the company reported a significant year-over-year sales decline of -12 %. However, it did see a marginal slip of -13.18 % from the previous quarter. Expenses decreased slightly by -14.61 % quarter-on-quarter, aligning with the annual decline of -15.97 %. Operating profit, while up 1360.87 % compared to last year, faced a quarter-on-quarter increase of 30.23 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 4.5 %, but an expansion of 1.6 % sequentially. Other income fell by -16.21 % compared to the last quarter, despite an annual growth of 63.67 %. Interest expenses dropped significantly by -10.53 % from the previous quarter, yet the year-over-year increase remains at a moderate 30.77 %. Depreciation costs climbed by 6.25 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 6.25 %. Profit before tax grew annually by 1362.5 % but saw an increase from the preceding quarter by 24.47 %.
Tax expenses as a percentage of profits decreased slightly by -155.4 % compared to last year, with a more notable quarter-on-quarter decrease of -2.37 %. Net profit rose by 1500 % year-on-year but experienced a 28.5 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 1511.48 % but a quarterly rise of 28.89 %. In summary, Samrat Pharmachem Ltd.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.

In reviewing Samrat Pharmachem Ltd.’s 2024-25(Q2) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -12 % year-on-year, although there was a slight dip of -13.18 % from the previous quarter. Expenses decreased by -15.97 % compared to the previous year, with a decrease of -14.61 % quarter-on-quarter. Operating Profit surged by 1360.87 % annually, and saw a 30.23 % increase from the last quarter.
Net Profit showed yearly increase of 1500 %, and experienced a 28.5 % increase from the previous quarter. Earnings Per Share (EPS) rose by 1511.48 % annually, however rose by 28.89 % compared to the last quarter. In essence, while Samrat Pharmachem Ltd. exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.